{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:57:38Z","timestamp":1781315858674,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["11C7623N"],"award-info":[{"award-number":["11C7623N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease which currently lacks effective treatments. Mutations in the RNA-binding protein FUS are a common cause of familial ALS, accounting for around 4% of the cases. Understanding the mechanisms by which mutant FUS becomes toxic to neurons can provide insight into the pathogenesis of both familial and sporadic ALS. We have previously observed that overexpression of wild-type or ALS-mutant FUS in\n                    <jats:italic>Drosophila<\/jats:italic>\n                    motor neurons is toxic, which allowed us to screen for novel genetic modifiers of the disease. Using a genome-wide screening approach, we identified Protein Phosphatase 2A (PP2A) and Glycogen Synthase Kinase 3 (GSK3) as novel modifiers of FUS-ALS. Loss of function or pharmacological inhibition of either protein rescued FUS-associated lethality in\n                    <jats:italic>Drosophila<\/jats:italic>\n                    . Consistent with a conserved role in disease pathogenesis, pharmacological inhibition of both proteins rescued disease-relevant phenotypes, including mitochondrial trafficking defects and neuromuscular junction failure, in patient iPSC-derived spinal motor neurons (iPSC-sMNs). In FUS-ALS flies, mice, and human iPSC-sMNs, we observed reduced GSK3 inhibitory phosphorylation, suggesting that FUS dysfunction results in GSK3 hyperactivity. Furthermore, we found that PP2A acts upstream of GSK3, affecting its inhibitory phosphorylation. GSK3 has previously been linked to kinesin-1 hyperphosphorylation. We observed this in both flies and iPSC-sMNs, and we rescued this hyperphosphorylation by inhibiting GSK3 or PP2A. Moreover, increasing the level of kinesin-1 expression in our\n                    <jats:italic>Drosophila<\/jats:italic>\n                    model strongly rescued toxicity, confirming the relevance of kinesin-1 hyperphosphorylation. Our data provide in vivo evidence that PP2A and GSK3 are disease modifiers, and reveal an unexplored mechanistic link between PP2A, GSK3, and kinesin-1, that may be central to the pathogenesis of FUS-ALS and sporadic forms of the disease.\n                  <\/jats:p>","DOI":"10.1007\/s00401-024-02689-y","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T01:02:33Z","timestamp":1708045353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-8158","authenticated-orcid":false,"given":"Paraskevi","family":"Tziortzouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-706X","authenticated-orcid":false,"given":"Jolien","family":"Steyaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Scheveneels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6102-9381","authenticated-orcid":false,"given":"Adria","family":"Sicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-2892","authenticated-orcid":false,"given":"Katarina","family":"Stoklund Dittlau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Margarida","family":"Barbosa Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-2936","authenticated-orcid":false,"given":"Thibaut","family":"Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7364-7791","authenticated-orcid":false,"given":"Andreas","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-2357","authenticated-orcid":false,"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-6257","authenticated-orcid":false,"given":"Thomas G.","family":"Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0104-4067","authenticated-orcid":false,"given":"Ludo","family":"Van Den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"2689_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/187152708783885110","volume":"7","author":"A Al-Chalabi","year":"2008","unstructured":"Al-Chalabi A, Tripathi VB (2008) Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 7:11\u201319. https:\/\/doi.org\/10.2174\/187152708783885110","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2689_CR2","doi-asserted-by":"publisher","unstructured":"Banerjee R, Chakraborty P, Yu MC, Gunawardena S (2021) A stop or go switch: glycogen synthase kinase 3\u03b2 phosphorylation of the kinesin 1 motor domain at Ser314 halts motility without detaching from microtubules. Development 148:dev199866. https:\/\/doi.org\/10.1242\/dev.199866","DOI":"10.1242\/dev.199866"},{"key":"2689_CR3","doi-asserted-by":"publisher","first-page":"110598","DOI":"10.1016\/j.celrep.2022.110598","volume":"39","author":"DM Baron","year":"2022","unstructured":"Baron DM, Fenton AR, Saez-Atienzar S, Giampetruzzi A, Sreeram A, Shankaracharya KPJ et al (2022) ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep 39:110598. https:\/\/doi.org\/10.1016\/j.celrep.2022.110598","journal-title":"Cell Rep"},{"key":"2689_CR4","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2174\/092986707782793862","volume":"14","author":"E Beghi","year":"2007","unstructured":"Beghi E, Mennini T, Bendotti C, Bigini P, Logroscino G, Chio A et al (2007) The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure. Curr Med Chem 14:3185\u20133200. https:\/\/doi.org\/10.2174\/092986707782793862","journal-title":"Curr Med Chem"},{"key":"2689_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.celrep.2018.06.070","volume":"24","author":"E Bogaert","year":"2018","unstructured":"Bogaert E, Boeynaems S, Kato M, Guo L, Caulfield TR, Steyaert J et al (2018) Molecular dissection of FUS points at synergistic effect of low-complexity domains in toxicity. Cell Rep 24:529-537.e4. https:\/\/doi.org\/10.1016\/j.celrep.2018.06.070","journal-title":"Cell Rep"},{"key":"2689_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.nbd.2017.04.010","volume":"105","author":"ST Brady","year":"2017","unstructured":"Brady ST, Morfini GA (2017) Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis 105:273\u2013282. https:\/\/doi.org\/10.1016\/j.nbd.2017.04.010","journal-title":"Neurobiol Dis"},{"key":"2689_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/brain\/awx370","volume":"141","author":"D Brenner","year":"2018","unstructured":"Brenner D, Yilmaz R, M\u00fcller K, Grehl T, Petri S, Meyer T et al (2018) Hot-spot KIF5A mutations cause familial ALS. Brain 141:688\u2013697. https:\/\/doi.org\/10.1093\/brain\/awx370","journal-title":"Brain"},{"key":"2689_CR8","doi-asserted-by":"publisher","first-page":"11224","DOI":"10.3390\/ijms222011224","volume":"22","author":"T Burg","year":"2021","unstructured":"Burg T, Rossaert E, Moisse M, Van Damme P, Van Den Bosch L (2021) Histone deacetylase inhibition regulates lipid homeostasis in a mouse model of amyotrophic lateral sclerosis. Int J Mol Sci 22:11224. https:\/\/doi.org\/10.3390\/ijms222011224","journal-title":"Int J Mol Sci"},{"key":"2689_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.celrep.2016.03.041","volume":"15","author":"JI Castillo-Quan","year":"2016","unstructured":"Castillo-Quan JI, Li L, Kinghorn KJ, Ivanov DK, Tain LS, Slack C et al (2016) Lithium promotes longevity through GSK3\/NRF2-dependent hormesis. Cell Rep 15:638\u2013650. https:\/\/doi.org\/10.1016\/j.celrep.2016.03.041","journal-title":"Cell Rep"},{"key":"2689_CR10","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/hmg\/ddab290","volume":"31","author":"H-J Choi","year":"2022","unstructured":"Choi H-J, Lee JY, Cha SJ, Han YJ, Yoon JH, Kim H-J et al (2022) FUS-induced neurotoxicity is prevented by inhibiting GSK-3\u03b2 in a Drosophila model of amyotrophic lateral sclerosis. Hum Mol Genet 31:850\u2013862. https:\/\/doi.org\/10.1093\/hmg\/ddab290","journal-title":"Hum Mol Genet"},{"key":"2689_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bbrc.2011.03.068","volume":"407","author":"J-Y Chuang","year":"2011","unstructured":"Chuang J-Y, Hung J-J (2011) Overexpression of HDAC1 induces cellular senescence by Sp1\/PP2A\/pRb pathway. Biochem Biophys Res Commun 407:587\u2013592. https:\/\/doi.org\/10.1016\/j.bbrc.2011.03.068","journal-title":"Biochem Biophys Res Commun"},{"key":"2689_CR12","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","volume":"23","author":"V Chung","year":"2017","unstructured":"Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS et al (2017) Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase i trial. Clin Cancer Res 23:3277\u20133284. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2299","journal-title":"Clin Cancer Res"},{"key":"2689_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/35096075","volume":"2","author":"P Cohen","year":"2001","unstructured":"Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769\u2013776. https:\/\/doi.org\/10.1038\/35096075","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2689_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/1535-7163.MCT-17-1143","volume":"18","author":"BM D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy BM, Swingle MR, Papke CM, Abney KA, Bouska ES, Prakash A et al (2019) The antitumor drug LB-100 is a catalytic inhibitor of protein phosphatase 2A (PPP2CA) and 5 (PPP5C) coordinating with the active-site catalytic metals in PPP5C. Mol Cancer Ther 18:556\u2013566. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1143","journal-title":"Mol Cancer Ther"},{"key":"2689_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.nbd.2017.02.004","volume":"105","author":"KJ De Vos","year":"2017","unstructured":"De Vos KJ, Hafezparast M (2017) Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis 105:283\u2013299. https:\/\/doi.org\/10.1016\/j.nbd.2017.02.004","journal-title":"Neurobiol Dis"},{"key":"2689_CR16","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1523\/JNEUROSCI.0172-14.2014","volume":"34","author":"Q Deng","year":"2014","unstructured":"Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M et al (2014) FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage. J Neurosci 34:7802\u20137813. https:\/\/doi.org\/10.1523\/JNEUROSCI.0172-14.2014","journal-title":"J Neurosci"},{"key":"2689_CR17","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/emboj.2010.143","volume":"29","author":"D Dormann","year":"2010","unstructured":"Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A et al (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 29:2841\u20132857. https:\/\/doi.org\/10.1038\/emboj.2010.143","journal-title":"EMBO J"},{"key":"2689_CR18","doi-asserted-by":"publisher","first-page":"11573","DOI":"10.1073\/pnas.0913138107","volume":"107","author":"J Du","year":"2010","unstructured":"Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R et al (2010) A kinesin signaling complex mediates the ability of GSK-3\u03b2 to affect mood-associated behaviors. Proc Natl Acad Sci 107:11573\u201311578. https:\/\/doi.org\/10.1073\/pnas.0913138107","journal-title":"Proc Natl Acad Sci"},{"key":"2689_CR19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nm.2396","volume":"17","author":"C D\u2019Ydewalle","year":"2011","unstructured":"d\u2019Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP et al (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17:968\u2013974. https:\/\/doi.org\/10.1038\/nm.2396","journal-title":"Nat Med"},{"key":"2689_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnmol.2011.00032","volume":"4","author":"H Eldar-Finkelman","year":"2011","unstructured":"Eldar-Finkelman H, Martinez A (2011) GSK-3 Inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 4:32. https:\/\/doi.org\/10.3389\/fnmol.2011.00032","journal-title":"Front Mol Neurosci"},{"key":"2689_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2015.10.030","volume":"359","author":"E Elert-Dobkowska","year":"2015","unstructured":"Elert-Dobkowska E, Stepniak I, Krysa W, Rajkiewicz M, Rakowicz M, Sobanska A et al (2015) Molecular spectrum of the SPAST, ATL1 and REEP1 gene mutations associated with the most common hereditary spastic paraplegias in a group of Polish patients. J Neurol Sci 359:35\u201339. https:\/\/doi.org\/10.1016\/j.jns.2015.10.030","journal-title":"J Neurol Sci"},{"key":"2689_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106177","volume":"40","author":"R Fazal","year":"2021","unstructured":"Fazal R, Boeynaems S, Swijsen A, De Decker M, Fumagalli L, Moisse M et al (2021) HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations. EMBO J 40:e106177. https:\/\/doi.org\/10.15252\/embj.2020106177","journal-title":"EMBO J"},{"key":"2689_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.expneurol.2003.10.004","volume":"185","author":"LR Fischer","year":"2004","unstructured":"Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A et al (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185:232\u2013240. https:\/\/doi.org\/10.1016\/j.expneurol.2003.10.004","journal-title":"Exp Neurol"},{"key":"2689_CR24","doi-asserted-by":"publisher","unstructured":"Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A, et al (2021) C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv 7:eabg3013. https:\/\/doi.org\/10.1126\/sciadv.abg3013","DOI":"10.1126\/sciadv.abg3013"},{"key":"2689_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20081135","volume":"415","author":"M Gardiner","year":"2008","unstructured":"Gardiner M, Toth R, Vandermoere F, Morrice NA, Rouse J (2008) Identification and characterization of FUS\/TLS as a new target of ATM. Biochem J 415:297\u2013307. https:\/\/doi.org\/10.1042\/BJ20081135","journal-title":"Biochem J"},{"key":"2689_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-1-4939-8897-6_10","volume":"1889","author":"D Gholobova","year":"2019","unstructured":"Gholobova D, Gerard M, Terrie L, Desender L, Shansky J, Vandenburgh H et al (2019) Coculture method to obtain endothelial networks within human tissue-engineered skeletal muscle. Methods Mol Biol Clifton NJ 1889:169\u2013183. https:\/\/doi.org\/10.1007\/978-1-4939-8897-6_10","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2689_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1083\/jcb.141.2.443","volume":"141","author":"JG Gindhart Jr","year":"1998","unstructured":"Gindhart JG Jr, Desai CJ, Beushausen S, Zinn K, Goldstein LSB (1998) Kinesin light chains are essential for axonal transport in drosophila. J Cell Biol 141:443\u2013454. https:\/\/doi.org\/10.1083\/jcb.141.2.443","journal-title":"J Cell Biol"},{"key":"2689_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.14336\/AD.2013.0400295","volume":"4","author":"PH Gordon","year":"2013","unstructured":"Gordon PH (2013) Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis 4:295\u2013310. https:\/\/doi.org\/10.14336\/AD.2013.0400295","journal-title":"Aging Dis"},{"key":"2689_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41467-017-00911-y","volume":"8","author":"W Guo","year":"2017","unstructured":"Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R et al (2017) HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun 8:861. https:\/\/doi.org\/10.1038\/s41467-017-00911-y","journal-title":"Nat Commun"},{"key":"2689_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.semcdb.2019.07.010","volume":"99","author":"W Guo","year":"2020","unstructured":"Guo W, Stoklund Dittlau K, Van Den Bosch L (2020) Axonal transport defects and neurodegeneration: molecular mechanisms and therapeutic implications. Semin Cell Dev Biol 99:133\u2013150. https:\/\/doi.org\/10.1016\/j.semcdb.2019.07.010","journal-title":"Semin Cell Dev Biol"},{"key":"2689_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primer 3:1\u201319. https:\/\/doi.org\/10.1038\/nrdp.2017.71","journal-title":"Nat Rev Dis Primer"},{"key":"2689_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/15384047.2015.1040961","volume":"16","author":"CS Hong","year":"2015","unstructured":"Hong CS, Ho W, Zhang C, Yang C, Elder JB, Zhuang Z (2015) LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther 16:821\u2013833. https:\/\/doi.org\/10.1080\/15384047.2015.1040961","journal-title":"Cancer Biol Ther"},{"key":"2689_CR33","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/genetics\/144.3.1075","volume":"144","author":"DD Hurd","year":"1996","unstructured":"Hurd DD, Saxton WM (1996) Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in drosophila. Genetics 144:1075\u20131085. https:\/\/doi.org\/10.1093\/genetics\/144.3.1075","journal-title":"Genetics"},{"key":"2689_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2014.11.003","volume":"74","author":"S J\u00e4ckel","year":"2015","unstructured":"J\u00e4ckel S, Summerer AK, Th\u00f6mmes CM, Pan X, Voigt A, Schulz JB et al (2015) Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiol Dis 74:76\u201388. https:\/\/doi.org\/10.1016\/j.nbd.2014.11.003","journal-title":"Neurobiol Dis"},{"key":"2689_CR35","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00018-019-03063-y","volume":"76","author":"P Javadpour","year":"2019","unstructured":"Javadpour P, Dargahi L, Ahmadiani A, Ghasemi R (2019) To be or not to be: PP2A as a dual player in CNS functions, its role in neurodegeneration, and its interaction with brain insulin signaling. Cell Mol Life Sci 76:2277\u20132297. https:\/\/doi.org\/10.1007\/s00018-019-03063-y","journal-title":"Cell Mol Life Sci"},{"key":"2689_CR36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski","year":"2009","unstructured":"Kwiatkowski TJ, Bosco DA, LeClerc AL, Tamrazian E, Vanderburg CR, Russ C et al (2009) Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205\u20131208. https:\/\/doi.org\/10.1126\/science.1166066","journal-title":"Science"},{"key":"2689_CR37","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1007\/s00018-021-03905-8","volume":"78","author":"F Liguori","year":"2021","unstructured":"Liguori F, Amadio S, Volont\u00e9 C (2021) Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers. Cell Mol Life Sci 78:6143\u20136160. https:\/\/doi.org\/10.1007\/s00018-021-03905-8","journal-title":"Cell Mol Life Sci"},{"key":"2689_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz H-J et al (2015) A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis 45:75\u201388. https:\/\/doi.org\/10.3233\/JAD-141959","journal-title":"J Alzheimers Dis"},{"key":"2689_CR39","doi-asserted-by":"publisher","first-page":"11697","DOI":"10.1073\/pnas.0905930106","volume":"106","author":"J Lu","year":"2009","unstructured":"Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R et al (2009) Inhibition of serine\/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci 106:11697\u201311702. https:\/\/doi.org\/10.1073\/pnas.0905930106","journal-title":"Proc Natl Acad Sci"},{"key":"2689_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1474-4422(10)70195-2","volume":"9","author":"IR Mackenzie","year":"2010","unstructured":"Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9:995\u20131007. https:\/\/doi.org\/10.1016\/S1474-4422(10)70195-2","journal-title":"Lancet Neurol"},{"key":"2689_CR41","doi-asserted-by":"publisher","unstructured":"Martineau \u00c9, Di Polo A, Vande Velde C, Robitaille R (2018) Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. eLife 7:e41973. https:\/\/doi.org\/10.7554\/eLife.41973","DOI":"10.7554\/eLife.41973"},{"key":"2689_CR42","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/ijms22168975","volume":"22","author":"L Mart\u00ednez-Gonz\u00e1lez","year":"2021","unstructured":"Mart\u00ednez-Gonz\u00e1lez L, Gonzalo-Consuegra C, G\u00f3mez-Almer\u00eda M, Porras G, de Lago E, Mart\u00edn-Requero \u00c1 et al (2021) Tideglusib, a Non-ATP competitive inhibitor of GSK-3\u03b2 as a drug candidate for the treatment of amyotrophic lateral sclerosis. Int J Mol Sci 22:8975. https:\/\/doi.org\/10.3390\/ijms22168975","journal-title":"Int J Mol Sci"},{"key":"2689_CR43","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1074\/jbc.M509806200","volume":"281","author":"JR McGuire","year":"2006","unstructured":"McGuire JR, Rong J, Li S-H, Li X-J (2006) Interaction of huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem 281:3552\u20133559. https:\/\/doi.org\/10.1074\/jbc.M509806200","journal-title":"J Biol Chem"},{"key":"2689_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrn3380","volume":"14","author":"S Millecamps","year":"2013","unstructured":"Millecamps S, Julien J-P (2013) Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 14:161\u2013176. https:\/\/doi.org\/10.1038\/nrn3380","journal-title":"Nat Rev Neurosci"},{"key":"2689_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-012-1043-z","volume":"125","author":"JC Mitchell","year":"2013","unstructured":"Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B et al (2013) Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol (Berl) 125:273\u2013288. https:\/\/doi.org\/10.1007\/s00401-012-1043-z","journal-title":"Acta Neuropathol (Berl)"},{"key":"2689_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/emboj\/21.3.281","volume":"21","author":"G Morfini","year":"2002","unstructured":"Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 21:281\u2013293. https:\/\/doi.org\/10.1093\/emboj\/21.3.281","journal-title":"EMBO J"},{"key":"2689_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065235","volume":"8","author":"GA Morfini","year":"2013","unstructured":"Morfini GA, Bosco DA, Brown H, Gatto R, Kaminska A, Song Y et al (2013) Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS ONE 8:e65235. https:\/\/doi.org\/10.1371\/journal.pone.0065235","journal-title":"PLoS ONE"},{"key":"2689_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40478-019-0715-5","volume":"7","author":"GM M\u00f3rotz","year":"2019","unstructured":"M\u00f3rotz GM, Glennon EB, Gomez-Suaga P, Lau DHW, Robinson ED, Sedl\u00e1k \u00c9 et al (2019) LMTK2 binds to kinesin light chains to mediate anterograde axonal transport of cdk5\/p35 and LMTK2 levels are reduced in Alzheimer\u2019s disease brains. Acta Neuropathol Commun 7:73. https:\/\/doi.org\/10.1186\/s40478-019-0715-5","journal-title":"Acta Neuropathol Commun"},{"key":"2689_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s40478-019-0857-5","volume":"7","author":"GM M\u00f3rotz","year":"2019","unstructured":"M\u00f3rotz GM, Glennon EB, Greig J, Lau DHW, Bhembre N, Mattedi F et al (2019) Kinesin light chain-1 serine-460 phosphorylation is altered in Alzheimer\u2019s disease and regulates axonal transport and processing of the amyloid precursor protein. Acta Neuropathol Commun 7:200. https:\/\/doi.org\/10.1186\/s40478-019-0857-5","journal-title":"Acta Neuropathol Commun"},{"key":"2689_CR50","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.neuron.2018.02.027","volume":"97","author":"A Nicolas","year":"2018","unstructured":"Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R et al (2018) Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97:1268-1283.e6. https:\/\/doi.org\/10.1016\/j.neuron.2018.02.027","journal-title":"Neuron"},{"key":"2689_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0014-5793(90)81435-Q","volume":"275","author":"S Orgad","year":"1990","unstructured":"Orgad S, Brewis ND, Alphey L, Axton JM, Dudai Y, Cohen PTW (1990) The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase I. FEBS Lett 275:44\u201348. https:\/\/doi.org\/10.1016\/0014-5793(90)81435-Q","journal-title":"FEBS Lett"},{"key":"2689_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.nbd.2007.02.005","volume":"26","author":"M Pantelidou","year":"2007","unstructured":"Pantelidou M, Zographos SE, Lederer CW, Kyriakides T, Pfaffl MW, Santama N (2007) Differential expression of molecular motors in the motor cortex of sporadic ALS. Neurobiol Dis 26:577\u2013589. https:\/\/doi.org\/10.1016\/j.nbd.2007.02.005","journal-title":"Neurobiol Dis"},{"key":"2689_CR53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.freeradbiomed.2020.06.028","volume":"159","author":"Z Qu","year":"2020","unstructured":"Qu Z, Sun J, Zhang W, Yu J, Zhuang C (2020) Transcription factor NRF2 as a promising therapeutic target for Alzheimer\u2019s disease. Free Radic Biol Med 159:87\u2013102. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.06.028","journal-title":"Free Radic Biol Med"},{"key":"2689_CR54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s40478-019-0750-2","volume":"7","author":"E Rossaert","year":"2019","unstructured":"Rossaert E, Pollari E, Jaspers T, Van Helleputte L, Jarpe M, Van Damme P et al (2019) Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. Acta Neuropathol Commun 7:107. https:\/\/doi.org\/10.1186\/s40478-019-0750-2","journal-title":"Acta Neuropathol Commun"},{"key":"2689_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","volume":"33","author":"T del Ser","year":"2013","unstructured":"del Ser T, Steinwachs KC, Gertz HJ, Andr\u00e9s MV, G\u00f3mez-Carrillo B, Medina M et al (2013) Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis 33:205\u2013215. https:\/\/doi.org\/10.3233\/JAD-2012-120805","journal-title":"J Alzheimers Dis"},{"key":"2689_CR56","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0092-8674(05)80065-0","volume":"71","author":"E Siegfried","year":"1992","unstructured":"Siegfried E, Chou T-B, Perrimon N (1992) wingless signaling acts through zeste-white 3, the drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate. Cell 71:1167\u20131179. https:\/\/doi.org\/10.1016\/S0092-8674(05)80065-0","journal-title":"Cell"},{"key":"2689_CR57","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41582-019-0257-2","volume":"15","author":"JN Sleigh","year":"2019","unstructured":"Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G (2019) Axonal transport and neurological disease. Nat Rev Neurol 15:691\u2013703. https:\/\/doi.org\/10.1038\/s41582-019-0257-2","journal-title":"Nat Rev Neurol"},{"key":"2689_CR58","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.cub.2015.06.045","volume":"25","author":"J Sreedharan","year":"2015","unstructured":"Sreedharan J, Neukomm LJ, Brown RH, Freeman MR (2015) Age-dependent TDP-43-mediated motor neuron degeneration requires GSK3, hat-trick, and xmas-2. Curr Biol 25:2130\u20132136. https:\/\/doi.org\/10.1016\/j.cub.2015.06.045","journal-title":"Curr Biol"},{"key":"2689_CR59","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1038\/ncomms4996","volume":"5","author":"R Stoica","year":"2014","unstructured":"Stoica R, De Vos KJ, Paillusson S, Mueller S, Sancho RM, Lau K-F et al (2014) ER\u2013mitochondria associations are regulated by the VAPB\u2013PTPIP51 interaction and are disrupted by ALS\/FTD-associated TDP-43. Nat Commun 5:3996. https:\/\/doi.org\/10.1038\/ncomms4996","journal-title":"Nat Commun"},{"key":"2689_CR60","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.15252\/embr.201541726","volume":"17","author":"R Stoica","year":"2016","unstructured":"Stoica R, Paillusson S, Gomez-Suaga P, Mitchell JC, Lau DH, Gray EH et al (2016) ALS\/FTD-associated FUS activates GSK-3\u03b2 to disrupt the VAPB\u2013PTPIP51 interaction and ER\u2013mitochondria associations. EMBO Rep 17:1326\u20131342. https:\/\/doi.org\/10.15252\/embr.201541726","journal-title":"EMBO Rep"},{"key":"2689_CR61","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.stemcr.2021.03.029","volume":"16","author":"K Stoklund Dittlau","year":"2021","unstructured":"Stoklund Dittlau K, Krasnow EN, Fumagalli L, Vandoorne T, Baatsen P, Kerstens A et al (2021) Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. Stem Cell Rep 16:2213\u20132227. https:\/\/doi.org\/10.1016\/j.stemcr.2021.03.029","journal-title":"Stem Cell Rep"},{"key":"2689_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-022-00591-3","volume":"18","author":"K Stoklund Dittlau","year":"2023","unstructured":"Stoklund Dittlau K, Terrie L, Baatsen P, Kerstens A, De Swert L, Janky R et al (2023) FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms. Mol Neurodegener 18:5. https:\/\/doi.org\/10.1186\/s13024-022-00591-3","journal-title":"Mol Neurodegener"},{"key":"2689_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1385\/1-59745-267-X:23","volume":"365","author":"M Swingle","year":"2007","unstructured":"Swingle M, Ni L, Honkanen RE (2007) Small molecule inhibitors of ser\/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol Clifton NJ 365:23\u201338. https:\/\/doi.org\/10.1385\/1-59745-267-X:23","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"2689_CR64","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","volume":"10","author":"B Swinnen","year":"2014","unstructured":"Swinnen B, Robberecht W (2014) The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10:661\u2013670. https:\/\/doi.org\/10.1038\/nrneurol.2014.184","journal-title":"Nat Rev Neurol"},{"key":"2689_CR65","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1042\/bj2840539","volume":"284","author":"A Takai","year":"1992","unstructured":"Takai A, Murata M, Torigoe K, Isobe M, Mieskes G, Yasumoto T (1992) Inhibitory effect of okadaic acid derivatives on protein phosphatases. a study on structure-affinity relationship. Biochem J 284:539\u2013544. https:\/\/doi.org\/10.1042\/bj2840539","journal-title":"Biochem J"},{"key":"2689_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1042\/bj2870101","volume":"287","author":"A Takai","year":"1992","unstructured":"Takai A, Ohno Y, Yasumoto T, Mieskes G (1992) Estimation of the rate constants associated with the inhibitory effect of okadaic acid on type 2A protein phosphatase by time-course analysis. Biochem J 287:101\u2013106. https:\/\/doi.org\/10.1042\/bj2870101","journal-title":"Biochem J"},{"key":"2689_CR67","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa E, Litvan I, H\u00f6glinger GU, Burn D, Lees A, Andr\u00e9s MV et al (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29:470\u2013478. https:\/\/doi.org\/10.1002\/mds.25824","journal-title":"Mov Disord"},{"key":"2689_CR68","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-510X(98)00137-3","volume":"159","author":"I Toyoshima","year":"1998","unstructured":"Toyoshima I, Sugawara M, Kato K, Wada C, Hirota K, Hasegawa K et al (1998) Kinesin and cytoplasmic dynein in spinal spheroids with motor neuron disease. J Neurol Sci 159:38\u201344. https:\/\/doi.org\/10.1016\/S0022-510X(98)00137-3","journal-title":"J Neurol Sci"},{"key":"2689_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41583-021-00431-1","volume":"22","author":"P Tziortzouda","year":"2021","unstructured":"Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 22:197\u2013208. https:\/\/doi.org\/10.1038\/s41583-021-00431-1","journal-title":"Nat Rev Neurosci"},{"key":"2689_CR70","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cub.2018.02.048","volume":"28","author":"A Vagnoni","year":"2018","unstructured":"Vagnoni A, Bullock SL (2018) A cAMP\/PKA\/Kinesin-1 axis promotes the axonal transport of mitochondria in aging drosophila neurons. Curr Biol CB 28:1265\u20131272.e4. https:\/\/doi.org\/10.1016\/j.cub.2018.02.048","journal-title":"Curr Biol CB"},{"key":"2689_CR71","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1242\/jcs.075168","volume":"124","author":"A Vagnoni","year":"2011","unstructured":"Vagnoni A, Rodriguez L, Manser C, De Vos KJ, Miller CCJ (2011) Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1. J Cell Sci 124:1032\u20131042. https:\/\/doi.org\/10.1242\/jcs.075168","journal-title":"J Cell Sci"},{"key":"2689_CR72","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","volume":"89","author":"RPA Van Eijk","year":"2017","unstructured":"Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN et al (2017) Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 89:1915\u20131922. https:\/\/doi.org\/10.1212\/WNL.0000000000004606","journal-title":"Neurology"},{"key":"2689_CR73","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"C Vance","year":"2009","unstructured":"Vance C, Rogelj B, Hortob\u00e1gyi T, De Vos KJ, Nishimura AL, Sreedharan J et al (2009) Mutations in FUS, an RNA Processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208\u20131211. https:\/\/doi.org\/10.1126\/science.1165942","journal-title":"Science"},{"key":"2689_CR74","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1038\/s41467-019-12099-4","volume":"10","author":"T Vandoorne","year":"2019","unstructured":"Vandoorne T, Veys K, Guo W, Sicart A, Vints K, Swijsen A et al (2019) Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nat Commun 10:4147. https:\/\/doi.org\/10.1038\/s41467-019-12099-4","journal-title":"Nat Commun"},{"key":"2689_CR75","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1083\/jcb.201407065","volume":"209","author":"KA Vossel","year":"2015","unstructured":"Vossel KA, Xu JC, Fomenko V, Miyamoto T, Suberbielle E, Knox JA et al (2015) Tau reduction prevents A\u03b2-induced axonal transport deficits by blocking activation of GSK3\u03b2. J Cell Biol 209:419\u2013433. https:\/\/doi.org\/10.1083\/jcb.201407065","journal-title":"J Cell Biol"},{"key":"2689_CR76","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/nn.3514","volume":"16","author":"W-Y Wang","year":"2013","unstructured":"Wang W-Y, Pan L, Su SC, Quinn EJ, Sasaki M, Jimenez JC et al (2013) Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat Neurosci 16:1383\u20131391. https:\/\/doi.org\/10.1038\/nn.3514","journal-title":"Nat Neurosci"},{"key":"2689_CR77","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.neurobiolaging.2014.07.035","volume":"36","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yang R, Gu J, Yin X, Jin N, Xie S et al (2015) Cross talk between PI3K-AKT-GSK-3\u03b2 and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging 36:188\u2013200. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.07.035","journal-title":"Neurobiol Aging"},{"key":"2689_CR78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/tra.12037","volume":"14","author":"C Weaver","year":"2013","unstructured":"Weaver C, Leidel C, Szpankowski L, Farley NM, Shubeita GT, Goldstein LSB (2013) Endogenous GSK-3\/shaggy regulates bidirectional axonal transport of the amyloid precursor protein. Traffic 14:295\u2013308. https:\/\/doi.org\/10.1111\/tra.12037","journal-title":"Traffic"},{"key":"2689_CR79","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/01677063.2016.1202950","volume":"30","author":"KR Weiss","year":"2016","unstructured":"Weiss KR, Littleton JT (2016) Characterization of axonal transport defects in Drosophila Huntingtin mutants. J Neurogenet 30:212\u2013221. https:\/\/doi.org\/10.1080\/01677063.2016.1202950","journal-title":"J Neurogenet"},{"key":"2689_CR80","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1186\/s13063-022-06906-5","volume":"23","author":"SW Willemse","year":"2022","unstructured":"Willemse SW, Roes KCB, Van Damme P, Hardiman O, Ingre C, Povedano M et al (2022) Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial. Trials 23:978. https:\/\/doi.org\/10.1186\/s13063-022-06906-5","journal-title":"Trials"},{"key":"2689_CR81","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1073\/pnas.0700493104","volume":"104","author":"FW Wolf","year":"2007","unstructured":"Wolf FW, Eddison M, Lee S, Cho W, Heberlein U (2007) GSK-3\/Shaggy regulates olfactory habituation in Drosophila. Proc Natl Acad Sci USA 104:4653\u20134657. https:\/\/doi.org\/10.1073\/pnas.0700493104","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-024-02689-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-024-02689-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T05:19:07Z","timestamp":1708319947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-024-02689-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1007\/s00401-024-02689-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.28.555106","asserted-by":"object"}]},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LVDB is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and\u00a0is also part of the Investment Advisory Board of Droia Ventures (Meise, Belgium).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"41"}}